Podcasts about Janssen

*This episode contains mature content. This week, we’ll hear from war correspondent Benjamin Hall, who has spent much of his career reporting from some of the world’s most dangerous conflict zones. In 2022, while covering the war in Ukraine, he was gravely injured in an attack that killed two of his colleagues. Today, he shares how that harrowing experience challenged his limits and instilled in him the unshakeable belief that we all have the strength to overcome—no matter what we face. Later in the episode, we’ll hear from author and life coach Chris Janssen as she shares her firsthand experience with alcoholism and the path to recovery. Now, through her journey of sobriety, Chris uses the lessons learned from her lowest moments to help others rise to new heights. Links, Products, and Resources Mentioned: Jesus Calling Podcast Jesus Calling Jesus Always Jesus Listens Past interview: Natalie Grant Upcoming interview: Jared Orton Jesus Calling commemorative edition Benjamin Hall Japanese prison camp War in Ukraine Kyiv Ukrainian Special Forces Fox News Save Our Allies Brooke Army Medical Center Psalm 23 NIV Resolute: How We Humans Keep Finding Ways to Beat the Toughest Odds Chris Janssen www.chrisjanssencoaching.com Grace Yourself: How to Show Up for the Sober Life You Want Interview Quotes: “I learned how much your mind can influence how you are feeling and how you can find another level of strength when you have to.” - Benjamin Hall “I do think that I must now live for those who died [in the car bombing I survived in Ukraine], and that I must challenge what I do for them. I make it drive me to be better, make it drive me to go into things that I think would inspire them and make them happy.” - Benjamin Hall “You mustn’t let fear disable you. You’ve got to address it, but also not run from it. I think that the worst thing you can do is hide from them, run from them, pretend they didn’t happen.” - Benjamin Hall “We are survival machines—humans. If you can channel your feelings, if you can talk to God, if you can find the strength you need, you can get through absolutely anything.” - Benjamin Hall “Everyone has resilience. I suppose what’s difficult is learning how to really use it. I always managed to find the beauty in every day while acknowledging loss. I think that’s something that is so important for people to learn—how to balance those two things in your life and not let the loss overwhelm you, but how to let the positive really guide you.” - Benjamin Hall “I just think anybody, regardless of how you grew up, can get caught in the snare of addiction.” - Chris Janssen “When the shame and guilt flew off my shoulders, my belief changed from I’m a monster to I’m deserving of recovery and community and sobriety because I’m addicted to alcohol.” - Chris Janssen “To me, physical wellness leads to emotional wellness.” - Chris Janssen “The way I describe sobriety is more than abstinence—it’s a lifestyle, not an event. I don’t believe I’m giving something up by sobriety, I’m gaining something. And what’s gained is my life, my memories, my presence with people, my ability to have fun.” - Chris Janssen “I felt like everything I did, I had to earn it, and that’s the opposite of grace. When we live in a mindset of control, we’re unable to accept grace. We’re taking control of our own worthiness, and we don’t get to do that. God has said we’re worthy and valuable no matter what.” - Chris Janssen ________________________ Enjoy watching these additional videos from Jesus Calling YouTube channel! Audio Episodes: https://bit.ly/3zvjbK7 Bonus Podcasts: https://bit.ly/3vfLlGw Jesus Listens: Stories of Prayer: https://bit.ly/3Sd0a6C Peace for Everyday Life: https://bit.ly/3zzwFoj Peace in Uncertain Times: https://bit.ly/3cHfB6u What’s Good? https://bit.ly/3vc2cKj Enneagram: https://bit.ly/3hzRCCY ________________________ Connect with Jesus Calling Instagram Facebook Twitter Pinterest YouTube Website TikTok Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts in the field to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children. To view the video version of this webinar, please click here. Disclosures:Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX TherapeuticsEric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkinJoy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

Sponsors: The Clergy Confessions Podcast (www.clergyconfessions.com); Gardner-Webb University School of Divinity (www.gardner-webb.edu); Baptist Seminary of Kentucky (www.bsk.edu); Baylor's Garland School of Social Work; The Community Transformation Center at Palm Beach Atlantic University (www.pbactc.org); The Center for Congregational Health (healthychurch.org); and The Baptist House of Studies at Union Presbyterian Seminary (www.upsem.edu/). Join the listener community at www.classy.org/campaign/podcast-…r-support/c251116. Music from HookSounds.com.

Send us a textAI promises to revolutionize clinical trials and reshape regulatory oversight. But is the pharma industry ready? And can the FDA keep pace with the technology? In this episode of the HealthBiz Podcast, host David Williams is joined by Tom Doyle, Chief Technology Officer of Medidata, to discuss the promises and potential pitfalls of AI in clinical trials.

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Christina Rahm, MS, PhD, EdD, is an internationally recognized entrepreneur, scientific leader, spokesperson, and innovator in the health and wellness space. Her overall approach to her groundbreaking work is to dismantle the barriers blocking the way to optimal health by identifying the root causes of issues and then addressing them scientifically and holistically.Full Podcast Link https://bit.ly/DrChristinaRahmPodcast A living embodiment of her motto, "The most important environment is yours," she travels the world presenting, lecturing, and educating the private and public sectors about the bold new world of nutraceuticals, wellness strategies, and environmental solutions, ultimately paving the way for the advancement of humanity. With multiple master's-level, doctoral-level, and honorary doctorate degrees in the fields of rehabilitation counseling, psychology, philosophy, and strategic sciences, Dr. Rahm also holds certifications from Harvard and Cornell in nanotechnology, nutrition, and pharmaceutical management. In addition to helming her own far-reaching enterprises, she has served as a medical, clinical, and research scientist for such notable pharmaceutical and biotechnology labs as Johnson & Johnson, UCB, Alexion, and Bristol Myers Squibb, and she has worked on the corporate side for Pfizer, Biogen, and Janssen, among others. A wife, mother, author, scientist, formulator, artist, influencer, and humanitarian, Christina Rahm is a powerhouse of energy and focus, devoted to human progress in all its forms and driven to contribute to positive change across the planet.

In this CME podcast episode, Dr. Andrew Cutler interviews Dr. Phillip Coffin, Director of the Center on Substance Use and Health in San Francisco, CA, about the management of stimulant use disorders. They explore the challenges of treatment and highlight the importance of harm reduction strategies to enhance patients' quality of life.  CME credit is available to NEI Members only.   Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Summarize pharmacologic and behavioral treatment strategies for stimulant use disorders, particularly methamphetamine and cocaine Evaluate the evidence base for current and investigational medications used in clinical trials and real-world settings Apply harm reduction principles and integrated care models to improve outcomes for patients with stimulant use disorders in diverse clinical settings Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: June 18, 2025*   Expiration: June 17, 2028 *NEI and HMP Education maintain a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-02.  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until June 17, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD, LFAPA specializing in psychiatry, forensic, addiction to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Phillip Coffin, MD, MIA Director of Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA No financial relationships to disclose. The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, Stephen Daniels and Bahgwan Bahroo, MD, LFAPA. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

This week's guest is Dutch visual journalist Bram Janssen. An old friend from the early Maboneng days, it was great to catch up and talk more about Bram's interesting career as a war photographer. Bram Janssen | InstagramRecommended Films & SeriesErnest Cole: Lost and Found (2024)Warfare (2025)Civil War (2024)The Greatest Beer Run Ever (2022) | Apple TV+Video Store LinksOfficial SiteHave a film or TV show you have recently enjoyed and want to let us know about it? Send us a voice note of you pretending you are coming in to the store to return it. Say your name, what you are returning, and what you think of it. Email it to us at the email address below, or DM us on instagram.Contact: thevideostorepod@gmail.com

TVC 694.5: Part 2 of a conversation that began two programs ago with Steve Aldous and Gary Gillies, co-authors of The Harry O Viewing Companion: History and Episodes of the Classic Detective Series, a deep dive into the making of Harry O (ABC, 1974-1976), the short-lived but fondly remembered private eye series starring David Janssen, Henry Darrow, and Anthony Zerbe, that also offers insight into what made Harry O so special. Topics this segment include Janssen's mounting frustration with ABC once each of the qualities that had made Harry O stand out from other private eye shows on television were slowly taken away once production of the series moved from San Diego to Los Angeles. The Harry O Viewing Companion is available wherever books are sold through McFarland Books.

We have a loving Heavenly Father who lovingly gives us what is ultimately good for us and for His glory.

The "Bros" host a SUPER SIZED two-hour episode discussing the importance of nutrition with registered dietitian and owner of Racer's Edge Nutrition Nicole Rubenstein, MS, RDN, CSSD, CDCES, world renowned spine surgeon, Ironman and offshore racing's Medical Director Dr. Michael Janssen and world champion offshore racer, Iconic Marine Group's Vice President of Product Development and President of the newly formed World Powerboat Racing Association Jeff Harris. The esteemed panel of guests explain how crucial it is to fuel the body properly and continuously, sometimes even more so than the boats that they race–for optimum performance and peak results. They also discuss the new WPRA and what it's all about.  Don't miss this extra large episode! Myrick Coil is the driver for the National Champion Monster Energy / M CON Class 1 team, Speedboat Magazine Test Team Driver, lead shop foreman at Performance Boat Center and a dedicated family man.  Ray Lee is the publisher of the national/international publication Speedboat Magazine, where nine high quality issues are printed each year with global distribution, and popular social media platforms on Facebook, Instagram and TikTok.  With all of the "Bros" experience, knowledge, and friends and colleagues in the industry and sport, this podcast is sure to entertain, enthuse and educate the powerboating community. 

We have a responsibility to share the best news ever!

David de Boer and Geert H. Janssen, eds. Refugee Politics in Early Modern Europe (Bloomsbury, 2024). This book is available as an open source publication here. Refugees have existed since ancient times but it was in the early modern era that they first became a distinct social and political category. This open access book maps the early modern 'invention of the refugee' and in the process uncovers their impact on local, regional, and transnational politics. With case studies ranging from Scandinavia to the Maghreb, Refugee Politics in Early Modern Europe traces how refugees transformed Europe. Topics explored include: the development of refugees as a political group in early modern societies; the role of displaced minorities in forging humanitarian networks; and the impact of refugees on migration management and imperialism. Most notably, this collection of essays moves beyond discussions of expulsion and flight to shine a spotlight on how states responded critically and constitutionally to refugees – as a means of galvanizing social groups, reinforcing identities, promoting activities, and expanding bureaucratic reach. The result is a sophisticated comparative study of migration, identity, power and politics which will be vital reading to all scholars of early modern Europe. The open access edition of this book is available under a CC BY-NC-ND 4.0 license on www.bloomsburycollections.com. Open access was funded by the Netherlands Organization for Scientific Research (NWO). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

David de Boer and Geert H. Janssen, eds. Refugee Politics in Early Modern Europe (Bloomsbury, 2024). This book is available as an open source publication here. Refugees have existed since ancient times but it was in the early modern era that they first became a distinct social and political category. This open access book maps the early modern 'invention of the refugee' and in the process uncovers their impact on local, regional, and transnational politics. With case studies ranging from Scandinavia to the Maghreb, Refugee Politics in Early Modern Europe traces how refugees transformed Europe. Topics explored include: the development of refugees as a political group in early modern societies; the role of displaced minorities in forging humanitarian networks; and the impact of refugees on migration management and imperialism. Most notably, this collection of essays moves beyond discussions of expulsion and flight to shine a spotlight on how states responded critically and constitutionally to refugees – as a means of galvanizing social groups, reinforcing identities, promoting activities, and expanding bureaucratic reach. The result is a sophisticated comparative study of migration, identity, power and politics which will be vital reading to all scholars of early modern Europe. The open access edition of this book is available under a CC BY-NC-ND 4.0 license on www.bloomsburycollections.com. Open access was funded by the Netherlands Organization for Scientific Research (NWO). Learn more about your ad choices. Visit megaphone.fm/adchoices

David de Boer and Geert H. Janssen, eds. Refugee Politics in Early Modern Europe (Bloomsbury, 2024). This book is available as an open source publication here. Refugees have existed since ancient times but it was in the early modern era that they first became a distinct social and political category. This open access book maps the early modern 'invention of the refugee' and in the process uncovers their impact on local, regional, and transnational politics. With case studies ranging from Scandinavia to the Maghreb, Refugee Politics in Early Modern Europe traces how refugees transformed Europe. Topics explored include: the development of refugees as a political group in early modern societies; the role of displaced minorities in forging humanitarian networks; and the impact of refugees on migration management and imperialism. Most notably, this collection of essays moves beyond discussions of expulsion and flight to shine a spotlight on how states responded critically and constitutionally to refugees – as a means of galvanizing social groups, reinforcing identities, promoting activities, and expanding bureaucratic reach. The result is a sophisticated comparative study of migration, identity, power and politics which will be vital reading to all scholars of early modern Europe. The open access edition of this book is available under a CC BY-NC-ND 4.0 license on www.bloomsburycollections.com. Open access was funded by the Netherlands Organization for Scientific Research (NWO). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/european-studies

On today's episode, Aimee is joined by founders of the Trail Mix Fund, Renee Jansen. The Trail Mix Fund is a non-profit working to improve diversity in trail racing by removing a potential barrier to entry. What started as a response to the COVID pandemic quickly turned into a powerful movement helping to diversify the trails - because everyone deserves a place at the start line.  Learn more about the Trail Mix Fund here: https://trailmixfund.org/ You can find more information about The Running Kind here. https://therunningkind.net/ https://www.facebook.com/groups/therunningkind/ @therunningkind_ If you are looking for additional ways to support The Running Kind, check out our Patreon page! patreon.com/TheRunningKind Aimee Kohler  Founder of The Running Kind @aimskoh Produced by Aimee Kohler Music Dim Red Light by Don Dilego  

In deze aflevering bespreken Juan en Marc de perfecte hoeveelheid bier. Stel je voor, de avond voor je ligt open. Er is bier voorhanden. Hoeveel bier drink je dan en waarom? Marc heeft een stout meegenomen, namelijk de Heel Stout BB van brouwerij Sancti Adalberti.  In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp.  

TVC 692.2: Steve Aldous and Gary Gillies, co-authors of The Harry O Viewing Companion: History and Episodes of the Classic Detective Series, talk to Ed about why Harry O has more in common with the Lew Archer novels by Russ MacDonald than the Raymond Chandler novels featuring Philip Marlowe or the Dashiell Hammett novels with Sam Spade; how David Janssen's skill at performing voice-overs was one of the ways in which he fully inhabited the Harry Orwell character; and how the onscreen rapport between Janssen and Anthony Zerbe changed the dynamics of Harry O for the better. The Harry O Viewing Companion is available wherever books are sold through McFarland Books.

Geen Europees voetbal volgend jaar. Dat is de pijnlijke conclusie na een bijzondere voetbalavond. De match stond bol van de narratieven (Janssen is terug en geeft voetballes! Bayo valt in en scoort eindelijk! De vreemde vroege invalbeurt voor Toby, die uiteindelijk nog een ultieme assist geeft!) - maar die leken een goede uitkomst van de wedstrijd eerder te verhinderen dan te bespoedigen. We bespreken hoe het zover is kunnen komen!Host: Thomas SlembrouckGasten: Dave Van Meel en Yoni Van LooverenMontage: Thomas Slembrouck Hosted on Acast. See acast.com/privacy for more information.

À l'occasion des 10 ans de Laurent Ruquier aux commandes des "Grosses Têtes", RTL vous propose chaque jour de revivre en podcasts les meilleures séquences de l'émission ! Aujourd'hui, découvrez un extrait du 25 mai 2023 ! Retrouvez tous les jours le meilleur des Grosses Têtes en podcast sur RTL.fr et l'application RTL.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

High Achievers and Perfectionists can find a way to self-sabotage their greatest callings. Chris Jansen, author and certified life coach, helps us apply grace, get clear on our why and bust through the lies we tell ourselves so that we can live the life God calls us to. Such an impactful episode. Listen in!Who is Chris:Chris is a board-certified coach with a master's in counseling psychology and over 25 years of experience working with hundreds of sought-after athletes, creatives, soldiers, entrepreneurs, and small businesses. She excels in helping high-achieving perfectionists navigate performance pressure, overcome self-sabotage and rewrite narratives. Chris trained with and worked on Tony Robbins' team of results coaches at the #1 personal development and peak performance strategy company in the world. Find her here:Website: https://www.chrisjanssencoaching.com/Instagram: https://www.instagram.com/chris3janssen/FaceBook: https://www.linkedin.com/in/chrisjanssencoaching/Linkedin: https://www.linkedin.com/in/chrisjanssencoaching/Books: https://www.amazon.com/author/chrisjanssen

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Everything else in this life is temporary and will fade away. But God is unfailing, unchanging, and ever-present.

True hope doesn't just comfort us—it compels us. It fuels a life of love, sacrifice,and service, even when it's hard. Romans 12 calls us to present our bodies asliving sacrifices and to live transformed lives that overflow with sincere love,patient endurance, and radical kindness—even to our enemies. It's powered byhope—a hope rooted in God's mercy and His unchanging promises.In a world where division and self-preservation are the norm, we're invited to bedifferent: to bless those who persecute us, to overcome evil with good, and to bemarked by a love that never gives up.

Podcast for a deep examination into the career and life choices of Eddie Murphy & Jim Carrey. Patrick gets transported to a living nightmare and there aren't even any pistachios for him. Joe can't remember what he's had for lunch, which isn't really a big deal, but it just kinda bugs him, you know. Lev worries he's upset the dog union by scabbing. What does that even mean? Find out on this week's episode of 'What the Hell Happened to Them?' Email the cast at whathappenedtothem@gmail.com Disclaimer: This episode was recorded in May 2025. References may feel confusing and/or dated unusually quickly. 'I Spy' is available on DVD, VHS, & Blu-ray (surprisingly): https://www.amazon.com/I-Spy-Blu-ray-Eddie-Murphy/dp/B07TMRS99F/ Music from "Dr. No vs Casino Royale" by Eventide Harmonizer Artwork from BJ West   quixotic, united, skeyhill, vekeman, murphy, carrey, versus, vs, I, spy, wilson, cosby, culp, bond, thomas, cole, mcdowell, janssen, budapest, ebert

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. •    Intro :24 •    The interview/about Stidham :36 •    Tell us about your family and where you grew up. 1:14 •    How did you embrace changes in technology growing up? 3:07 •    What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator?  6:05 •    What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 •    Can you give a quick overview of what these tools and technologies entail?  12:52 •    What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 •    Where did your interest in AI come about? 20:26 •    You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 •    How do we change the way we train GI doctors, and should we start making these changes today? 26:38 •    With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 •    What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 •    What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 •    Thank you, Ryan 44:04 •    Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

It is the Gospel of Jesus that will transform a person and a nation.

Dan Janssen, founder and creative director of Lincoln Design Co., returns to the show for a deep dive into the studio's highly anticipated new release: The Brand Design of a Brand Design Agency. This 288-page book isn't about client work—it's a behind-the-scenes look at how Lincoln built its own brand from the inside out. Packed with unreleased logos, illustrations, internal marketing, swag, and studio stories, the book is a decade-in-the-making tribute to what happens when a studio treats itself like its most important client.In this episode, we unpack the big ideas behind the book, why it exists, who it's for, and how it challenges the traditional rules of branding and self-promotion. Dan shares lessons learned from building a dream studio culture, creating products that leave lasting impressions, and the importance of documenting your creative evolution.We also talk about the value of getting outside the design bubble. Fresh off Crop Con in Austin and gearing up for the Licensing Expo in Vegas, we swap insights on how conferences, both design-focused and industry-specific—can fuel creativity, spark collaborations, and push your studio's visibility beyond the usual crowd.If you're a designer, creative director, studio owner, or student looking to understand what it really takes to build a brand-first creative business, this one's for you.

MUSICINTHEAIR @Villahangar #PodcastShow THIS WEEK presents >> @romyjanssen [EPISODE 400-20] TRACKLIST: 01. Osfur, UVITA, The Scripture - Pieces [Armada Music Albums] 02. Kgzoo, Loving - On My Mind [Calamar Records] 03. Tripolism, Nandu - Sunrise [Ultra Records] 04. JUNO (DE) - Last Dance [Magnifik Music] 05. Ajna (BE), Marlin (BE) - Bottom [Magnifik Music] 06. Marten Lou - Your Body [Warner Music Central Europe] 07. Florence + The Machine - Dog Days Are Over (Anton Khabbaz Remix) 08. Bruno Martini - Beautiful (Romy Janssen Remix) [Beeside Records] 09. The Blaze - Territory (SOMMA Remix) [Animal63] 10. Oliver Koletzki feat. Malou - Is It Real [Stil vor Talent] 11. FiNE, Romy Janssen, Tabia - Ubuntu [Sippy Time] 12. Bedouin, Iveta Mukuchyan - Make Me Feel (Notre Dame Remix) [Human By Default] Site -> www.villahangar.com FB -> www.facebook.com/villahangar TT -> www.twitter.com/Villahangar

Have a question you want answered on the podcast? Send us a text!Are you a high-achiever who feels like no success is ever enough? Struggling with perfectionism, pressure, or self-sabotage — but not sure why you can't move past it?In our latest episode, we interview Chris Janssen, MA, BCC, a leading results coach and author of Grace Yourself: How to Show Up for the Sober Life You Want. We dive into the hidden struggles high performers face, like unnoticed emotional wounds and limiting beliefs that quietly derail progress.Left unaddressed, these patterns can lead to burnout, addiction, and deep dissatisfaction. But change is possible — and it starts with understanding the real root of the problem.If you're ready to break free from old patterns and build a life rooted in true self-worth, this conversation is for you!Subscribe & ReviewSubscribing and leaving a rating and review are important factors in helping the Reshape Your Health Podcast and the YouTube Channel reach more people. If you haven't already subscribed, please do that today.We would also be grateful if you left a rating and review, too. In your listening app, scroll to the “Ratings and Reviews” section, then click “Write a Review” and let us know what you enjoy about our show. We appreciate you taking the time to show your support. Thank you! Resources From The Guest>> Chris Janssen's Website>> Chris Janssen's Facebook>> Chris Janssen's Instagram>> Chris Janssen's AmazonResources From This Episode >> Insulin Resistance Diet Blueprint - https://www.zivli.com/blueprint?el=podcast >> Free Low Insulin Food Guide - https://www.zivli.com/ultimatefoodguide?el=podcast >> Join the Zivli Program Waitlist - https://www.zivli.com/join?el=podcast >> Test Your Insulin at Home - https://www.zivli.com/testing?el=podcast Have a question? Email us at: support@zivli.com

Recorded live at One Heart Church (Port Lincoln) at the 9:00 am service on 4th of May, 2025.

Send us a textWe are BACK on The Construction Life—this time for a powerful conversation with the incredible Jennifer Janssen. From the Netherlands to Canada, Jennifer's journey is all about resilience, clarity, and staying grounded in a high-pressure world.We dive into: 

Send us a textDr. Shelley Janssen is the Chief Medical Officer at Doctors Care in South Carolina, and a candidate for the Board of Directors of the Urgent Care Association.

Against all odds, Abraham believed — fully convinced of God's unshakable faithfulness. Unlike the world's fleeting promises, God's Word stands secure. Join us as we dive into the limitless power of His promises!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly is currently involved in a legal battle with compounders over knockoff versions of tirzepatide, marketed as Zepbound for weight loss. The FDA has prohibited compounders from producing these knockoffs after confirming the end of the tirzepatide shortage in December 2024. On the other hand, BMS is facing disappointment with Cobenfy's late-stage failure in treating schizophrenia, marking their second high-profile setback in recent weeks. RFK is contemplating removing COVID-19 from the CDC's vaccine guidelines for children to align with other countries and the WHO. Biotech investors are navigating a turbulent period due to new tariffs and economic uncertainty, causing additional upheaval in an already fragile market. Trump is looking to reinstate international drug pricing policies, while Swiss ADC Biotech is opting for the SPAC route to Nasdaq.Summit's bispecific has outperformed another cancer medication, putting pressure on Keytruda's dominance. In the midst of this biotech downturn, Wacker Biotech is offering advanced therapy process development and production services. Moving on to the next news, executives in the pharmaceutical industry often receive substantial golden parachutes upon leaving a company. Pfizer is defending its cardiac blockbuster drug against competition from Alnylam and BridgeBio. The biotech sector was showing signs of a rebound until new tariffs and economic uncertainty introduced further instability.Lilly is pursuing legal action against compounders for producing counterfeit drugs, while Roche and Regeneron are committing billions to US manufacturing amidst tariff challenges. The industry is undergoing significant changes under the current administration, with opportunities to learn from global markets. Challenges such as investor pullback and market volatility are impacting the biotech sector.Janssen's departure from Galapagos and the promising future of all-American biotech companies are also discussed. Stay tuned for more updates on upcoming events and job opportunities in the field.

In this episode, host Tyler Chisholm is joined by Cory Janssen, co-founder and co-CEO of AltaML, to explore the next frontier of artificial intelligence—and what it means for Alberta's innovation economy. Cory breaks down how AltaML is helping organizations move from pilot projects to production-scale applications, using industry-specific AI agents to automate complex workflows in construction, healthcare, and beyond. The conversation covers the promise and pitfalls of AI, from the risks of model bias to the future of regulation and global competitiveness. With a focus on applied innovation and responsible deployment, Cory shares why Alberta's talent, values, and entrepreneurial drive make it a prime location to lead in the emerging agentic AI era.This episode is brought to you by clearmotive marketing. When it comes to marketing that truly matters to your business, clearmotive is your go-to partner. With a proven track record of more than 15 years, they understand what makes your business tick. Learn more at https://www.clearmotive.ca and discover how clearmotive can help your marketing thrive.We're on social media! Follow us for episodes you might have missed and key insights on Western Canada directly on your feeds.Instagram: https://www.instagram.com/collisionsyycLinkedIn: https://www.linkedin.com/company/collisions-yycYouTube: https://www.youtube.com/@collisionsyycWebsite: https://www.collisionsyyc.comThank you for tuning into Collisions YYC!Remember to subscribe and follow us on Spotify and Apple Podcasts so you never miss an episode.If you loved the episode, please leave us a 5-star review and share the show with your friends! These things really help us reach more potential fans and share everything that's amazing about Western Canada.We sincerely appreciate your support of our local podcast.Host links:Tyler's website: https://www.tylerchisholm.comTyler's LinkedIn: https://www.linkedin.com/in/tylerchisholmGuest links:Cory Janssen's LinkedIn: https://www.linkedin.com/in/coryjanssenAltaML's Website: https://www.altaml.comAltaML's LinkedIn: https://www.linkedin.com/company/altamlAltaML's Twitter: https://www.twitter.com/altaml_comAltaML's Instagram: https://www.instagram.com/altaml_comAltaML's TikTok: https://www.tiktok.com/@altaml.comCollisions YYC is a Tyler Chisholm original production // Brought to you by clearmotive marketing

Vanessa and Jerome interview Ginger and Robb Janssen to discuss off-grid living and their business, Basalt Mountain Gardens. Since 1994 the Janssens have been creating, expanding, and enjoying their off-grid paradise on Basalt Mountain.

Regular listeners to Unstoppable Mindset have heard me talk about a program called Podapalooza. This event takes place four times a year and is attended by podcasters, people who want to be podcasters and people who want to be interviewed by podcasters. Featured podcasters such as I get to talk with a number of people who sign up to be interviewed by us specifically.   This past Podapalooza saw me get to meet our guest this time, Susan Janzen. Susan wasn't even on of my original matches at Podapalooza, but she and I met and she told me she wanted both to be on Unstoppable Mindset and for me to come on her podcast, “Living & Loving Each Day”. Well, part one has happened. Susan has come on Unstoppable Mindset, and what a remarkable and unstoppable person she is.   Throughout her life she has been a professional singer and recording artist, a special education teacher, a realtor, now a life coach and she, along with her husband Henry, Susan has authored two books.   Make no mistake, Susan has performed all these life experiences well. She has been a singer for more than 30 years and still rehearses with a big band. She was a substitute special education teacher for six years and then decided to switch from teaching to selling real estate to help bring accessible housing to Alberta Canada.   Susan, as you will discover, is quite an inspiration by any standard. I look forward to receiving your comments and observations after you hear this episode. I am sure you will agree that Susan is quite Unstoppable and she will help you see that you too are more unstoppable than you think.       About the Guest:   Susan is an inspiring professional whose achievements span multiple fields. As a professional singer and recording artist, she enchanted audiences across North America. Her legacy as Edmonton's first Klondike Kate includes captivating performances from Las Vegas to the Alberta Pavilion during Expo 1987. Her versatility shines through her educational pursuits, earning a Bachelor of Education and influencing lives as a Special Education teacher. Alongside her husband, Dr. Henry Janzen, Susan co-authored two Amazon Best Sellers, further cementing her creative impact. Empowering Lives Through Coaching and Music Today, Susan combines her passions: Performs with the Trocadero Orchestra, a 17-piece Big Band. Empowers others as a Certified Happy for No Reason Trainer and Jay Shetty Life Coach. Hosts her podcast, Living & Loving Each Day Bridging Barriers sharing powerful stories of overcoming challenges.   Ways to connect Susan:   https://www.facebook.com/home.php https://www.youtube.com/@SusanJanzen www.linkedin.com/in/susan-janzen-b-ed-5940988 https://www.instagram.com/livingnlovingbridgingbarriers/   About the Host:   Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog.   Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards.   https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/   accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/   https://www.facebook.com/accessibe/       Thanks for listening!   Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below!   Subscribe to the podcast   If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can subscribe in your favorite podcast app. You can also support our podcast through our tip jar https://tips.pinecast.com/jar/unstoppable-mindset .   Leave us an Apple Podcasts review   Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.       Transcription Notes:   Michael Hingson ** 00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us.   Michael Hingson ** 01:20 Well, hi everyone. I am your host, Mike hingson, and you are listening to unstoppable mindset podcast, unstoppable mindset where inclusion, diversity and the unexpected meet, and that's always so much fun. So we do some, we do sometimes talk about inclusion, and we do talk about diversity, and we talk about inclusion first, because diversity usually leaves out disabilities, but in this case, we we like inclusion because we won't let anyone leave out disabilities if they're going to talk about being inclusive. So there you go. But anyway, even more important than that is the unexpected, which is anything that doesn't have anything to do with diversity or inclusion, our guest today kind of has a little bit to do with all of that stuff. Susan Janzen is our guest. I'm assuming I'm pronouncing that right, perfectly, right? Yes, perfect. And Susan is up in Edmonton, Canada, and I met Susan a couple of weeks ago because both of us participated in the patapalooza program. Patapalooza, for those of you who may be listening to this on a regular basis, patapalooza is a program that happens four times a year where people come on who want to be podcasters, who are podcasters, or who want to be interviewed by podcasters. And we all kind of get together and we talk, and we listen to some lectures, and a bunch of us go off into breakout rooms and we get to chat with people. And when I was being scheduled, Susan was not one of the people who, in fact, got scheduled with me, but she came into the room and she said, I want to talk to you. And so there we are. And so Susan, welcome to unstoppable mindset where we can talk.   Susan Janzen ** 03:12 Well, so glad and so glad to be in a room with you here on my screen. This is great. Oh, it's fun.   Michael Hingson ** 03:18 My door is closed so my cat won't come in and bug me, because every so often she comes in and and what she wants is me to go pet her while she eats, but I'm not going to let her do that while the podcast is going on. So there you go. But anyway, it's good to be here, and I'm glad that you're here with us, and I understand that it's kind of nice and crisp and chilly where you are right now. No surprise, we are much more weak,   Susan Janzen ** 03:45 yeah, much warmer. There we had in Alberta. We're always in Edmonton, Alberta. We're called the sunny province because it's doesn't matter how cold it gets. We always have blue cumulus clouds and beautiful blue sky   Michael Hingson ** 04:00 and so. And today you have and today it's my cold.   Susan Janzen ** 04:04 It's, well, it's minus 10 with a skiff of snow. But you know what? Minus 10 here is? Actually, that's kind of my prerequisite for skiing, like, if it's minus 10 or warmer, I'm good, because I'm not a very good added skier. That's why   Michael Hingson ** 04:20 my brother in law used to ski on a regular basis. He in fact, used to take trips and take tours and and allow people to hire him as their tour guide to go over to France to do off peace school in the else. And he is also a cabinet maker and general contractor, and Gary's philosophy always is everything stops in the winter when there is an opportunity to ski. So   Susan Janzen ** 04:50 that would be a beautiful wouldn't that be there? Like the perfect job to probably be a golf pro in the summer in a ski tour? Third guide in the winter. Well,   Michael Hingson ** 05:01 he he was a, he was a contractor in the summer. Now he's doing more contracting all year round. He still skis, but he's not a certified mountain ski guide in France anymore. I think, I assume that kind of runs out after a while, but he hasn't really taken people on trips there for a while. But anyway, we're really glad you're here. I would love to start by maybe you telling us a little bit about the early Susan, growing up and all that well,   05:27 with the early Susan, that sounds great. Sure,   Susan Janzen ** 05:28 let's do   05:30 it that was a long,   Michael Hingson ** 05:32 long time ago in a galaxy far, far away. But let's do it anyway, exactly,   Susan Janzen ** 05:36 exactly. So way back in the day I was, I was actually my history is, is from I had a mother who was a singer, and she and I, I'm also professional singer, but she, she was my influence when I was younger, but when I was born, it was out those terminology at that time was called out of wedlock. Oh my gosh, you know, so bad. And so she was a single mom, and raised me as a very determined and and stubborn girl, and we had our traumas, like we went through a lot of things together, but we survived, and we're and we're, you know, all the things that I went through, I was on in foster care for a little while, and I kind of did a whole bunch of different things as a kid, and went on my own When I was 15. So I left home when I was 15, so I figured I'd be on my own. I figured I was mature enough to just go on my own, right like that made was made total sense and perfect sense to me at the time, and now I realize how young 15 is, but but finished high school and went to on the road and was a singer for like, over 25 years. That's better that. And, yeah. And so that's what I that was kind of like the childhood part of me. And that's, I think, what's putting me into all these play. I was in a convent for a while with   Michael Hingson ** 06:54 honey, and so you, you went off and you sang, you said, for 25 years, yes,   Susan Janzen ** 07:01 and I'm still singing. I'm still singing. That was Yeah.   Michael Hingson ** 07:06 And I was reading that you sing with a seven piece, 17 piece, Big Band orchestra. I do.   Susan Janzen ** 07:12 It's called a Trocadero orchestra. It's so it's the whole horn section, the the rhythm section. It's so much fun, I can't tell you, so I we do that. We don't gig a lot because a lot of people don't want to put out the money for an ATP spend. But we do rehearse a lot, and we do the big, big events in the city. It's really fun. What kind of music? So big bands, so 40s, yes, and so all the Oh, exactly. We can do the Latin stuff I sing that's in mucho the same mucho is one of my songs. And I do, you know, there's so many, like, so many really good songs, but they're older songs that kind of the Frank Sinatra kind of era songs, all the big band stuff. I've   Michael Hingson ** 07:56 always thought that Bing Crosby was a better singer than Frank Sinatra. That's gonna probably cause some controversy. But why that?   Susan Janzen ** 08:04 I wonder. But you know what big, big Crosby was a little bit before, and then Frank Sinatra was called the crooner, and I think it was because of his blue eyes and how he looked. I think he took on a different persona. I think that's why I think it was more the singer than more the singer than the music. Maybe you think, I don't know. I   Michael Hingson ** 08:25 haven't figured that out, because Bing Crosby was, was definitely in the 40s. Especially, was a more well known, and I think loved singer than Frank. But by the same token, Frank Sinatra outlive Bing Crosby. So, you know, who knows, but I like being Crosby, and I like his music, and I like some Frank Sinatra music as well. I mean, I'm not against Frank Sinatra, yeah. I think, personally, the best male singer of all time. Yes, still, Nat King Cole   Susan Janzen ** 09:00 Oh, and I do? I do the dot I do orange colored sky neck and Cole's daughter, yeah, this one on my brain. Her name Natalie Cole, exactly. Yeah. But Nat King Cole was a really good singer, so I do agree with you in that. And we do some that can cool stuff. I do a lot of Ella Fitzgerald too, as well.   Michael Hingson ** 09:24 Yeah. Well, I, I've always liked and just felt Nat King Cole was the best of now, female singers, probably, again, a lot of people would disagree, but I really think that Barbara Streisand is, oh, there is.   Susan Janzen ** 09:37 I love her. Yeah, yeah, I did. I actually, I did an album. In the 719, 78 I recorded an album, and the main song on there was evergreen by Barbra Streisand. I   Michael Hingson ** 09:48 love that tune. Yeah, I was. I just have always liked Barbara Streisand. One of my favorite albums is Barbara Streisand at the forum. She James Taylor. And I forget who the third person was. Did a fundraiser for George McGovern in 1972 and I just always thought that that was Barbara's Best Album.   Susan Janzen ** 10:10 Ah, so such a voice. I mean, she could see anything. Yeah. Beautiful voice, yeah, I agree. I agree. Well, we're on the same page, yeah.   Michael Hingson ** 10:19 Well, that's pretty cool. But so you, you grew up, you sang and and then what happened to you, or what did you do? What, what else occurred in your life that we should know about?   Susan Janzen ** 10:31 Oh, there's so many things. So then I, yeah, I know it's crazy. So I grew up, I think I still, I'm not quite there yet. I'm still growing. And then I when at 18, I got married, and I went on the road with a guitar player, and for 10 years, and then we had two kids. And then after five more years on the road, I actually got a divorce. And so I was six years as a single mom with two babies. The kids were, like, 11 months apart. They were really close. And so then that's when I did all my bigger gigs here in Edmonton, though, those are the like. I was hired as the first ever local Klondike Kate in Edmonton, Alberta. We have Klondike. We used to have Klondike games as our major summer fair, and it was a really big deal. It's kind of like the Calgary Stampede we had the Edmonton on Lake Bay, and so I was the representative of the city of Edmonton for two years. And I actually did it my first year. They made me audition for my second year. So I won it the second year. So I was the first ever two years in a row. And I represented the city all over North America. Actually, I sang, I met Muhammad Ali, I met some really great people, and I sang with Baba patola, did some commercials with him, went down to Vegas and played one of his stages. So I did a lot of really fun things in those two years, and convert a lot of commercials and a lot of telethons. So that was really fun. And then, and then, when that was over, that's when I got remarried to a wonderful man, and he was at University of Alberta, and he was a professor in psychology, education, psychology and so and I'm happy to say that we're just celebrated last week our 36th wedding anniversary. That's how old I am. Michael, congratulations.   Michael Hingson ** 12:18 Well, my wife, my wife and I were married for 40 years, and she passed in November of 2022, so, oh, so I I know what it's like to be married for a long time. I loved it. Love it. Still wonderful memories. It's unfortunate that all too many people don't ever get to have the joy of being married for such a long time. Yes,   Susan Janzen ** 12:43 and happily married, right? Like happily married? Yeah, that's the cavid.   Michael Hingson ** 12:50 Yeah. It's important to to acknowledge the happiness part of it. And I've got 40 years of memories that will never go away, which is great.   Susan Janzen ** 12:58 Nobody can take that away from you, that is for sure. They can't take that away from me. Don't take that away from me. That's   Michael Hingson ** 13:06 right, exactly. So that's that's pretty cool. So you do a lot of rehearsing and a lot of singing. What else do you do in the world today? So also   Susan Janzen ** 13:15 in the world today, I am, and I have been since 2003 I'm a residential real estate expert, so I'm a realtor, and I deal specifically with accessible and barrier free homes. So that's kind of my I was a special ed teacher. Actually, I should squeeze that in there for six years I was, I got my degree in education and with a special ed teacher in secondary ed. So all my kids were junior and senior high. And then when I came out of that, I took up the after I was teaching. I took real estate license, and I got it and I I just felt like I understood anybody with mobility challenges and with any other challenges. And so I took that extra time that is needed and necessary to to help them find homes and to sell.   Susan Janzen ** 14:02 What got you started down that road   Susan Janzen ** 14:05 at the time, I was teaching for six years, and when in Edmonton, I don't know why it was just here. So I was 2003 when I quit. So I had been teaching from the late 1990s and it was like I was subbing, but I was not getting a full time position in that and my Evanston public school board said your your file is glowing. We just don't have any spots for you. So I think it was a government funding issue. And so I ended up just thinking, I don't want to sub forever. I want to get my own classroom, and I want to have my own and I would, I would teach for six months at a time in a school. So it wasn't like I was jumping around crazy but, but I want, really wanted my own classroom. And so when that wasn't happening after six years, I thought I'm going to write the real estate license exam, and if I pass it the first time, that was my Gage, because no, they say the word was that you don't pass it the first time. Everyone has to write it to a. Three times before they pass my rule. For my own ruler for me was to say, if I take the exam, pass it the first time, I will make that move. And that's what happened so and then I just took up with accessible, barrier free homes and that specialty. So   Michael Hingson ** 15:17 was there any specific motivation that caused you to really deal with accessibility and accessible homes and so on.   Susan Janzen ** 15:25 Yes, and at the time, and just actually, my mom had been in a walker and on oxygen. I had quite a few friends who had mobility issues. And then just shortly after that, when I was a realtor already, and my daughter had a baby, and her baby at eight weeks old had a near SIDS incident. So she was eight weeks old, and Candace went to do the dishes one night at nine o'clock at night, and came back and calea is her daughter's name, and she was like blue in the crib. She was she had to be revived. So that was terrifying for all of us, and so it was wonderful news that she did survive, but she had occipital and parietal damage, so she has cortical vision impairment and also cerebral palsy, but she's she's thriving and loving it, and so that actually kind of Got me even doing more accessible homes, because now I'm a grand ambassador, and what's that called when you get out on the street and yell at people for parking in handicap stalls? What is that smart person? A smart person, and I was just passionate about that. I wanted to fix things and to try to make things easier for people as they should be, without having to ask in the first place. So yeah, so that's kind of the other reason I stuck to the that that area in real estate, and I just had the patience for it. I had the knowledge and the understanding and I and I really it was just easy for me because I did. I think it was because the passion I had for that area, and I just love doing it and helping other people   Michael Hingson ** 17:05 well. So how old is your granddaughter now? Now she is 12. Okay, she's 12. Now, does she walk, or does she use a wheelchair?   Susan Janzen ** 17:13 She uses, um, well, because she is as tall as me now, oh, she's using more a wheelchair more often, okay? She She walks with a walker. She can't walk on her own at all, and I think it's because of the vision, right? She if she could, you know, yeah, if she could see, she sees light. It's amazing how that how the brain works. She sees lights, and she sees color. And I can put up any color to her, and she'll identify it right every time, every time, but she doesn't see me. She doesn't see my face. Well, tell   Michael Hingson ** 17:45 me a little bit more about cortical vision. You. You and I talked about that a little bit. So Lacher, yeah, explain that to people. It's   Susan Janzen ** 17:52 really interesting because it's something that it's not readily out there, like you don't hear about it a lot. And even as a special ed teacher, I can tell you that I was trained in all of the different areas of special needs, but that did not come up for me, so this was new when I found out about it, and it just means that her eyes are fine. There's nothing wrong with her eyes, but her she's not processing so the information is coming through her eyes, but she's not processing that information. But she, like I said, if I turn out the light, she'll go, oh, the lights are off. Or if I put the lights on, she'll look up and be surprised at it. She you can tell that she knows. And then I used to put her on my counter in the kitchen, and I had these LED lights underneath my counter, my kitchen counter, and it had all these, these 12 different colors of light, and so I would put the blue on, I'd say, calea, what color is that? And she'd go blue, and I'd say, What color is that, and she'd go red. So it would be variable colors that I'd offer up to her, and she wouldn't get them right every single time. So that's the cortical vision impairment, and where they if she needs to pick up something off of a dresser, off the floor, for instance, it has to be on like a black background, and then she can see it, no problem. But if you have a whole bunch of things on the ground or on the table and ask her to pick up something, that's too much information for her, so she can't just zero in on that one area, right? So it's harder for her. So you just have to make things more accessible, so that she can see things you know, in her way.   Michael Hingson ** 19:25 But this is a different thing than, say, dyslexia, which is also you can see with your eyes, but your brain is in processing the characters and allowing you to necessarily truly read it exactly. And   Susan Janzen ** 19:38 that's that different part of the brain, where it's analyzing the the at least you can you can see it, but you process it differently. That's exactly right where she can't see. So then that's why I was thinking, if she could see better, I think she would be walking, maybe with a cane or with a walker, better. But right now, in that. Stage, we can point her in the right direction and tell her to go, and she'll go, but she's not sure where she is.   Michael Hingson ** 20:08 But that clearly wasn't the start of you doing real estate sales, dealing with accessible homes, but it must have certainly been a powerful motivator to continue with exactly   Susan Janzen ** 20:20 that, exactly that, because my mom was on oxygen, and she had, she had a lot of issues, mobility challenges. And I had a lot of friends who who were also like in that older age group that had mobility challenges. And those are the people that that were, may say, moving from a two story to a bungalow because they couldn't make manage the stairs anymore.   Michael Hingson ** 20:41 So how do we get people like the Property Brothers? Do you ever watch them and you know who they are? Oh yes, oh yes. We get them to do more to deal with building accessibility into the homes that they built. Because the the issue is that we have an aging population in our world. And it just seems like it would be so smart if they built accessibility and rights from the outset in everything that they do, because the odds are somebody's going to need it   Susan Janzen ** 21:11 exactly. And that's the for the forward thinking, right? You know? And it's interesting that some people, some builders, have told me that just to make a door frame three inches wider does not cost you any more money. But the point, the point is just that it's getting all the contractors on board to to come out of the way that they've been doing it for so long. You know, sadly,   Michael Hingson ** 21:38 yeah, my wife was in a chair her whole life, she was a teacher, paraplegic. Oh, so you know, I know about all this really well. And in fact, when we built this house, we we built it because we knew that to buy a home and then modify it would cost a bunch of money, one to $200,000 and in reality, when we built this house, there was no additional cost to make it accessible, because, as you point out, making doors wider, lowering counters, having ramps instead of stairs, all are things that don't cost more If you design it in right from the outset, exactly,   Susan Janzen ** 22:24 exactly, and that's that's the problem. Yeah, that's the problem. I mean, that's exactly the problem.   Michael Hingson ** 22:29 Yeah. Now we built our home in New Jersey when we moved back there, and we did have a little bit of an incremental extra cost, because all the homes in the development where we found property were two story homes, so we did have to put in an elevator, so it's about another $15,000 but beyond that, there were no additional costs, and I was amazed that appraisers wouldn't consider the elevator to be an advantage and an extra thing that made The home more valuable. But when we did sell our home in New Jersey, in fact, the elevator was a big deal because the people who bought it were short. I mean, like 5253, husband and wife, and I think it was her mother lived with them, and we put the laundry room up on the second floor where the bedrooms were, and so the elevator and all that were just really wonderful things for everyone, which worked out really well.   Susan Janzen ** 23:30 Oh, that's perfect. And that's, that's kind of what I do here in evident that I try to match the people who are selling homes that have been retrofitted and made more, you know, accessible. I try to put out the word that this is available, and I try to get the people in who need that. I feel like a matchmaker, a house matchmaker, when it comes to that, because you don't want to waste that like some people, actually, they'll some people who don't understand the situation have chairless For instance, they they're selling their house, and they rip out the chair. Then it's like, well, call me first, because I want to find you somebody who needs that, and that's exactly what they're looking for. Okay, so that's kind of where, how I I operate on my my job   Michael Hingson ** 24:15 well, and I will tell you from personal experience, after September 11 for the first week, having walked down 1400 63 stairs and was stiff as a board for a week, I used the elevator more than Karen did. Oh,   Susan Janzen ** 24:28 at that, but you survived that. And that was, that's amazing, but it   Michael Hingson ** 24:35 was, yeah, you know, you have to do what you gotta do. I think that there's been a lot more awareness, and I I've been back to the World Trade Center since, but I didn't really ask, and I should have, I know that they have done other things to make it possible to evacuate people in chairs, because there were a couple of people, like, there was a quadriplegic. Um. Who I believe is a distant cousin, although I never knew him, but he wasn't able to get out, and somebody stayed with him, and they both perished. But I think that they have done more in buildings like the World Trade Center to address the issue of getting people out.   Susan Janzen ** 25:17 It's just too bad that we have to wait for that, things, terrible things like that to happen to crazy awareness. That's the only bad thing. What? It's not like, it's not like we're not yelling on the streets. It's not like we're not saying things. It's just that people aren't listening. And I think it depends on if you're to a point where you are actually in a wheelchair yourself, or you have a child who's in a wheelchair now, now they understand, well,   Michael Hingson ** 25:43 yes, it is getting better. There's still a lot of issues. Organizations like Uber still really won't force enforce as they should. All the rules and regulations that mandate that service dogs ought to be able to go with Uber passengers who have a need to have a service dog, and so there, there's still a lot of educational issues that that have to occur, and over time will but I think that part of the issue was that when 2001 occurred, it was the right time that then people started to think about, oh, we've gotta really deal with this issue. It is an educational issue more than anything else. That's true. That's   Susan Janzen ** 26:26 true. There's a fellow here in Edmonton that, and I'm sure it's elsewhere too, but one particular fellow that I know, and he builds, they're called Garden suites. Like in Edmonton, we're kind of getting so much the population here is standing so quickly that the city is allowing zoning for they're called Garden suites, so they're just but he goes in and puts in like a two story behind the home, and it's 100% accessible, barrier free, and no basement. And so we're encouraging people to buy those homes, and they don't cost as much because they're quite a bit smaller. They're only two bedroom but they have everything that anybody would need if they had mobility challenges. And so it's it's perfect for either people who have a son or a daughter who is getting close to being an adult and they want their more a little more freedom and independence. They could use that suite at the back. Or I know some adults in particular who are have mobility challenges, and they just physically move to that new place in the backyard and rent out their home right to make home revenue.   Michael Hingson ** 27:31 Since it's two stories, what do they do to make it accessible? They   Susan Janzen ** 27:34 have, they have an elevator. It's a zero entry, and it's 100% everything in it is specifically so you move in, walk, go right in, and it's, it's accessible. That's how he does it, right from scratch. Cool, super cool. And so we're trying to, I'm trying to promote that here, out here, because I, I know the fellow who builds them, and it makes sense. I mean, even if you want to have a revenue property, right? And you want to build that in your backyard and then rent it out to somebody who needs that, then that'd be perfect.   Michael Hingson ** 28:06 It makes, makes a lot of sense to do that. It does. Mm, hmm. Well, do you think that all of the knowledge that you gained in special education and so on has helped you a great deal in this new, more, newer career of doing real estate sales.   Susan Janzen ** 28:25 Oh, 100% because it's just an understanding. It's just having the compassion and understanding what not, because I haven't experienced it myself, but I do understand what they may be going through. It's just an enlightening for me, and I I just appreciate what they're going through, and I am, you know, I want to make it easier for them, you know, to make any decisions that they have to make. And I try. I don't like, I don't waste their time like, I make sure I go preview the homes first, make sure that it's something and I FaceTime them first to say, is this something you want to even come out to? So I don't want them to be wasting their time or their energy just trying to get to a place that's not accessible,   Michael Hingson ** 29:05 right? Mm, hmm. We moved from New Jersey to Novato California, which is in the North Bay, which is now being just bombarded by rain, but Northern California in 2002 and when we started looking for homes, we tried to find a place where we could build, but there was just no place up there where there was land to build a home. So we knew we had to buy a home and modify it. And one day, we went with a realtor, and he took us to a house, and it was clearly a house that wasn't going to work. The this there were, there was no room to put in a ramp, there were lots of steps, and we pointed out all the reasons that it wouldn't work. And then he took us to another home that was really like the first one. We went to four different homes and. We kept saying, this won't work, and here's why, and it was like a broken record, because it was all the same. I'm so sorry. Yeah, you know, I realized that not everyone has the opportunity to really understand and learn about wheelchair access and so on. But people should focus more on on doing it. It wasn't like I needed a lot for the house to be usable by me as a blind person, but, but Karen certainly did. And what we eventually found another realtor took us to a place, and what was really interesting is we described what we wanted before we started looking at homes with Mary Kay, and she said, I have the perfect home. You'll have to modify it, but I have the perfect home. And of course, after our experiences with the other realtors, we were a little bit pessimistic about it, but she took us to a home, and there was a step up into it, but that's easy to modify. Then you go through an entryway, and then you can go left into the kitchen or right, and if you went right, you ended up in a little Nexus where there were three bedrooms, oh, and it wasn't even a hallway. There were just three bedrooms. And so it was, it was perfect. We still had to make significant modifications, but it really was a home that was modifiable by any standard, and we, we bought it. It was perfect   Susan Janzen ** 31:44 for what we needed. I'm so glad I love that's a good start. That's a good story here. Yeah,   Michael Hingson ** 31:50 she, she got it and and it's so important. And I think Realtors need to be aware of the fact that we deal with a very diverse population, and it's important to really understand all of the various kinds of people that you might have to deal with, but we just don't always see that. Needless to say,   Susan Janzen ** 32:08 that's true. Unfortunately, that's so true. Yeah.   Michael Hingson ** 32:14 So do you how? How much time do you spend doing real estate? Is that a full time job for you.   Susan Janzen ** 32:20 Well, it always has been. I've been full time, full service, so I'm on call, really is kind of what it boils down to. But I've also pursued, in the last since COVID, I've pursued coaching courses because that's something I'd like to get into. And so now I'm a certified Jay Shetty resilience and confidence coach, and so I'm kind of leading, I think, as I age and as I, you know, getting tired of I've been a realtor 21 years now, so I would like to eventually slow down in that area and focus more on coaching people. That's kind of where I'm leaning now a little bit, but I'm still full time up there. And singer   Michael Hingson ** 33:02 and singer and your coach, yeah. So do you ever see your coaching customers? Just check, no no   Susan Janzen ** 33:10 checking. I send them the recording. I'll send them my CD. You can go and get you could get two of my CDs on iTunes, so I'll send them there, or else tell them one of my geeks.   Michael Hingson ** 33:20 Oh, cool. Well, I'll have to go look you up on iTunes. I have, yes, oh, it   Susan Janzen ** 33:25 is a Christmas there's a Christmas one there. I think you'd like that. Michael, is it really cool?   Michael Hingson ** 33:29 And I have Amazon unlimited music. I wonder if. I'll bet there too. You   Susan Janzen ** 33:33 just take in. Susan Jansen, and I come up. I have the greatest love of all is my one, and the other one's called the gift for you, and that's my Christmas split. Oh,   Michael Hingson ** 33:41 cool, yeah. Well, we will. We will check them out, by all means. Well, so when do you rehearse? When do you when do you do singing?   Susan Janzen ** 33:52 Well, the big band rehearses every Saturday. So we, we all get together and we do. So it's, I just, you know, I love the rehearsals, like it's so much fun for me. So that's what we do with my other singing. I still get I still get hired, especially during the summer festival time, I get hired to come back and we call it throwback Klondike dates. And I have one costume of all my costumes that were made for me this you can imagine my costumes is called that Kate were like, a lot of sequins, full dresses with the big furry bottoms and then the feathery hats. So I used to wear those. So I still have one costume that still fits me, and so I use that every summer, and I go out, and I'm asked to do different functions during the summer, and then during all throughout the year, I do parties, you know, like, what if somebody hires me to do a birthday or some special celebration? I still do that. Okay, so   Michael Hingson ** 34:47 how often does the big band actually go out and perform and earn some money? Or does that happen much at all? Not that much because of   Susan Janzen ** 34:54 the size of us, right? Yeah. So, you know, we've done, you know, like the 100th anniversary of Arthur. Is a dance floor. And so we did their 100th anniversary celebration. And can you imagine, like the dance floor was just, it was like I was watching my own show from from the stage, because they we did all the Latin tunes, and they came out and danced the Sava and the rambas and the tangos and everything. It was beautiful. So I got to so that was a really fun gig for us, and then, and so we do other big and larger functions, like in ballroom. So you can imagine a conference, perhaps that's having a big celebration will be the ballroom entertainment. Well,   Michael Hingson ** 35:32 you know, you're in Canada. Can't you get Michael Buble to hire you guys? Ooh,   Susan Janzen ** 35:35 wouldn't that be nice? He's got his own man. He's   Michael Hingson ** 35:39 got, yeah, he does. I know these old charts and yeah, but he occasionally brings to the choir. I know that we, we went to see him well. Karen passed in November of 2022 we actually went to see him in Las Vegas in May of 2022 that was the last concert that we got to do together. And we ended up being relocated from up in the balcony in what Henry, what Harry Belafonte, would call the scholarship section. We We got moved down to the orchestra pit, and we were like in row 18, even two rows in front of Michael's family, but we ended up being there for the concert. It was wonderful. Oh, and he walked out and shook hands with everyone while he was singing, and all that was a lot of fun. But, yeah, he does have his own band, but music's great,   Susan Janzen ** 36:36 so good, and he does that so well. Like my favorite show is the voice. And so he's a judge on there too, and I really appreciate input. And he comes off very Canadian. I think he's this is very friendly and very silly and fun and and just really caring too. So I think he represents us well on the voice.   Michael Hingson ** 36:56 He does not take himself too seriously, which is so important, I think for so many people, so true. He does so well with that. So true. Well, so we mentioned pada Palooza, and you have a podcast. Well also, and you, you've written a book, right?   Susan Janzen ** 37:14 Yes. So I've co authored a few books, and then, plus my husband and I Well, my husband actually is a psychologist. He wrote the book, I typed it, and then he gave me credit, because I kept putting in my own stories and and he would, he was kind enough to put my name on the cover. So and we wrote a book called living and loving each day. And that's how, why I made my podcast that same name, and, and, but when we wrote it, the full title is living and loving each day success in a blended family. Because at that time when we got married, I had the two children, and they were just under you know, they were nine and 10 years old, eight and nine years old, and his boys, he had three boys that were older, like teenagers, and so and his wife passed away from cancer. So we all got together. And I mean blended families, that's a whole nother world, you know, if you're not used to that, that's something else. And, and then it turned out that his oldest son was diagnosed schizophrenic, so that was something that we dealt with together as a family. And, and, and then yeah we so we just felt like this was our life, and we wanted to share that. But that's like combining two separate families together, and how that works, and the dynamics of that. So he wrote some great, great stuff about how to deal with in laws, X laws and outlaws. He called them Yeah, and how to deal with every family celebration, Christmas and Easter, everything you know, like, there's so many things that come up even think about until you're in that situation, like, how do you do it? Right?   Michael Hingson ** 38:52 But it's so great that you two made the choice to do it and to blend the families and not give up on each other, or any of the people in the family, exactly,   Susan Janzen ** 39:04 and that's in that's huge for me. And I can share a little story with you. Feel like the view is okay. So this is kind of cool. So this so when I was singing, and I was just at the end of my second year as Klondike Kate, and I was doing a lot of gigs, like a lot of singing and and I was just kind of cut, you know how they like you're, you see on the calendar that they're you're tuning down here. The end of the year is coming. The end of the gigs are coming, and you're not in that role anymore because they chose a new Klondike. And so those six years that I was a single mom, my husband now had his own radio show, and it was called that's living and there was a show out of Edmonton, and it actually won Canadian awards for this was a talk show during the day for one and a half hours, and it had two psychologists, and the psychiatrists were the hosts. And so on the Tuesdays and Thursdays with Dr Jan, that was my husband and I used. To listen every day because I had, I was a single mom. I really didn't have a lot of support, and I worked every night singing so and I had my kids all day. So it was just like my favorite show to listen to. And when I remember listening to and I heard this Dr Johnson's voice, I always thought he had, like, long white hair, long white beard, so he was just so calm and so compassionate and so smart that he was just such a I never knew what he looked like, but that's what I pictured him looking like. And then it turned out that right at the end of my my singing, I remember listening one day, and he was on the air, and he I was going to my agents I was driving down Main Street in Edmonton, and I remember going to my agent's office to see what was next for me, like, what's next? What next gig do I have? And I remember he came on the air that day, and he said, You know what, folks, I have to let you know that his he said, My wife passed away. And he said, My boys and I've been grieving since the day we found out six months ago. But I need to be here to be of service to you, and I need to be on the air to help you today. And hope you don't mind. I hope you understand, you know he was, you know, and it was, it was so emotional, and like I was sitting in my van, like crying, thinking, because I'd been listening to him all those years, and I just felt so sad for him. And then I kind of, I'm a God fearing woman, and I said, Lord, why can't I meet a man like that that needs me as much as I need him. That was my outside prayer. And you know what? It wasn't even a week and a half later, I get a call from that station, CTC, saying, hey, Sue, can you do a Christmas Bureau fundraiser for us? He said, There's no pay involved, but you can be MC and and, you know, help us. You know, raise money for the Christmas funeral. And so I was happy to do that. And so that's how, how I met my husband was when at that particular function. So that was kind of my, you know, and like, just an answer to prayer and something that I really, you know, it was interesting how, how that all happens when you are very specific and, and so that's how we met. And, yeah, so we've been together ever since 36 years now. Well,   Michael Hingson ** 42:06 as I tell people, you know, Karen passed away two years ago, and I don't move on from Karen, but I move forward exactly because I think if I I've always interpreted Moving on is you go on and you forget, and I don't, and I don't want to forget, so I move forward Exactly. And besides that, I know that if I misbehave, I'm going to hear about it, so I gotta be a good kid, or she's going to get me one way or another. Yeah, that's right. And so, you know, as I, as I said to somebody yesterday, I don't even chase girls, so you know, it works out very well, but you know, the the the issue is that those 40 years of memories are always going to be there, and there's so much to learn from that. And again, it's all about choice. This is so important well, so tell us more about the podcast on how long have you been doing it? How did that start? And and so on,   Susan Janzen ** 43:03 right? So I was actually my daughter has this a nonprofit where she was she works with other parents who have children with adaptive needs, and so she asked if I would interview her parents just to find out about parents stories and you. I'm sure you understand where you want to just tell your story, what happened without having to explain. And, you know, I don't know, just give all the, you know, the background to everything. They just wanted to share this story and to be heard on with no judgment and with compassion. So I said, No, I can do that. I can interview them, and I want to hear their stories. And they need, I think they need to share them those stories too, for whatever happened, you know, with whatever incident happened with their children. So, so I said to my daughter, I sure I'll do a podcast for them, you know, and just interview them. And then I only did it through zoom and not knowing anything about how to do that, I've been MC for fundraisers, but I don't know how to do a podcast. So I did that the best I could, using Zoom. And then I when I was done it, I liked it so much, I thought, well, I better figure out how to do this, like the right way, right? So I actually did take a course. And there was a lady out of Toronto that was giving a course called cash in on camera. And so she talked about how to set up restream, how to set up air table, how to do your mic, your lighting, and all of the things that you need to consider. And so I took that course. And so then I interviewed a few more people and a few experts for her, for her. So that's kind of how I got started, with just focusing specifically on on my daughter's audience. So those parents.   Susan Janzen ** 44:40 And how long ago was that?   Susan Janzen ** 44:41 That was, what, two years ago now total, because I've been doing my podcast now for just over a year.   Susan Janzen ** 44:48 And do you how many episodes a week? Do you do one?   Susan Janzen ** 44:51 I do one, but I, you know what? I've got 140 that I've done. And I'm thinking, I've got quite. If you in the books, you know how that works. Where you report I'm you, Michael, give me advice on this. So I have three recorded that are waiting for me, but plus I have 14 others that are on my book to interview like I'm getting a lot of interest and people who want to be on my podcast, which is wonderful, but then I got, now gotta figure out how to do that, or how to actually, you know, organize it. How often should I be putting out podcasts? Like every three days now, like otherwise, we're going to be going into middle of 2025 I don't know.   Michael Hingson ** 45:33 I started for accessibe, doing unstoppable mindset in August of 2021 when I started using LinkedIn seriously to look for podcast guests in 2022 and I use sales navigators, so we profile authors or coaches or whatever, and we'll send out emails saying, I saw your profile. It looks like you'd be an interesting guest. Would you love to explore coming on unstoppable mindset, what we do is then we, when they're willing, we schedule a meeting and we we talk about it, and if they want to come on, which usually they do, then we actually schedule the time, and I ask them to send me some information, as you know, like a series of questions that they want to talk about, a bio, other things like that, but we got a pretty significant backlog. And I've learned that a lot of people with very successful podcasts do have backlogs. Oh, good. There's nothing wrong with that. Okay, good. It's better to have them. You can always add an extra podcast if you want to play more, but we do two a week now, and just today, we published episode 286, wow. Since August of 2021, and so it's a lot of fun. I enjoy it, and I get to meet so many people. And as I tell people, if I'm not learning at least as much as anyone who listens to the podcast, I'm not doing my job well. I agree, quite invested in it. I think it's so important to be able to do that. So the bottom line is that we do get a lot of interesting people. I talked to someone just the other day who is very much involved in energy and healing and so on. Well, she also was a singer in Australia, had a very serious auto accident, and kind of went away from seeing for a while, and then she realized she started doing a lot of creating, of affirmations, but then she put the affirmations to music, and she points out that, you know, the lyrics are in the left side of the brain, but the music's in the right side, and they actually work together, and so by having them in a musical form, you you're more likely to really be able to internalize them. So she even sang one for us on the earth, a lot of fun, but, but the bottom line is that, you know, it's she also does her own podcast, which is kind of fun, but there is so much to learn from so many different people. I've had so much fun doing it, and I enjoy very much the opportunities to learn. Yeah,   Susan Janzen ** 48:29 no, I'm right there with you, and I think that's why I just keep going, because it's fascinating. And then, and it seems like the right different people come into my, my, you know, my area, just to ask if they can be on it. And it's, it always works out really well, like it's always something that else that I've just kind of broadens it a little bit, but I, I'm trying to be more focused this night, last two months now, in that, you know, in conjunction with my daughter and just doing the parents with accessible, you know, needs, or kids with adaptive needs. And also, some adults are coming to me now too, saying they've in their 30s and 40s, they were in psycho with ADHD, and so they're that diverse, neuro, diverse group. So, I mean, who knows where that will take me, right? I'm open to it   Michael Hingson ** 49:18 well, and that's what makes it so much fun. You never know where the journey is going to take you, or if you do, and you're all embracing it, so much the better. But if you don't know what's an adventure, and that's good too, that's   49:28 great. No, I agree with you, yeah. So I love how   Michael Hingson ** 49:31 many, how many pot of Palooza events have you been to? That   Susan Janzen ** 49:34 was my first one. I know I did not have a clue what to expect. I put you down as my potential guest, though, but I don't know how it didn't come up forward. So I'm glad we're doing this now, but I I really enjoyed it. I love the people, and you could tell we were all in the same room with the same visions and the same, you know, compassionate areas that we're working in. So. I was really grateful for a lot of the people I met, great people. Well   Michael Hingson ** 50:03 now you and I also have an event time scheduled next Tuesday. Do we good? Yeah, are you? Well, you scheduled it in my Zoom. But if you, if you, when you go look at your calendar, you'll see, I think what you did was you scheduled it, forgetting this was supposed to be a 60 minute interview conversation. But if you send me a link, this is live radio sports fans. If you send me a link, then I will come to yours next time, next Tuesday, at the time that we're supposed to meet, rather than you coming into the Zoom Room, where we are, or I can make you a co host, and you can record it your choice.   Susan Janzen ** 50:45 Oh, what? Hey, yes, let's do it. Okay,   Michael Hingson ** 50:49 I'll just, we'll, we'll get together, and I'll make you a host or a co host, that'd be perfect.   Susan Janzen ** 50:54 And then you can record it that'd be great. Or, I have three streams, so I can send you the link for that you   Michael Hingson ** 51:01 choose, but long as it's accessible to screen readers, I'm happy. And,   Susan Janzen ** 51:09 yeah, thank you for that, Michael, I did. We'll do that. You got it good. We're booked. Yeah, we are   Michael Hingson ** 51:16 already booked. So it's next Tuesday, so that'll be good. That'll be great, but it's a lot of fun.   Susan Janzen ** 51:23 Yeah, really it's it's nice to get to know people. It's really nice to know other people's journeys. And especially, what I find most fascinating is all over the world, like we're meeting people that we would have never met. Yeah, you know before. So I'm glad. I really   Michael Hingson ** 51:36 appreciate that I've met a number of people from Australia. We interviewed? Well, we had a conversation with somebody from Uganda, number of people in England and people throughout the United States. So it's a lot of fun.   Susan Janzen ** 51:49 It really is, yeah, so we're blessed that that's great. It's a   Michael Hingson ** 51:53 wonderful blessing. I mean, doing this is so enjoyable. I used to do radio in college, and so this the neat thing about doing a podcast, at least the way I do it, is you're not absolutely governed by time, so you don't have to end at four o'clock and and it's so much more fun than radio, because you are the one that's really in control of what you do. So it's it's a lot of fun, but I very much enjoy doing the podcast, right?   Susan Janzen ** 52:23 You're right is that if they start having to go to worship break and not have to take the time and stopping and starting, that is really,   Michael Hingson ** 52:30 oh, that people seem to like it. They they keep emailing me and saying they like it. And I, I'm hoping that they continue to do that. As long as people are happy with me doing it, I'm going to do it. And you know, as I tell everyone, if you know anyone who ought to be a guest on unstoppable mindset, want to hear from you and provide us with an introduction, because it is part of what we do. And so, so much fun,   Susan Janzen ** 52:53 so much fun. So tell me why you Why did you choose that name unstoppable mindset?   Michael Hingson ** 52:59 You know, I was looking for a name. And I've heard some people kind of talking about unstoppable in their lives in some way, but I also thought that we really needed to define what unstoppable meant. And so I just thought about it for a while, and it just really kind of clicked. And I said, Okay, God, that must be what you want me to do. So we're going to have unstoppable mindset. We're inclusion, diversity in the unexpected beat. Love it and it's and it is stuck. And every title for people starts with unstoppable. So you'll be unstoppable something or other. I gotta think about the title, unless you've got some bright idea.   Susan Janzen ** 53:48 Oh yeah, you have to let me know.   Michael Hingson ** 53:51 Well, I'm trying to use something like unstoppable. Woman of many talents. But you know,   Susan Janzen ** 53:56 yeah, I don't have just 111, little lane. I love learning about everything, and I love open and grateful for every opportunity. So that's probably my problem. Yeah, that's our problem. That's not really a problem, but I know it's not,   Michael Hingson ** 54:11 and it's so much fun. So what are your goals for the podcast? How do you hope it will make a difference in the world?   Susan Janzen ** 54:21 I think my, my biggest thing is to say, you know, I've been through, I think it's showing people that they're not alone, that there are people out there who do understand, and there are people there that really do care about them, and that we want to provide information and services, and we want to hear their story. We want them to just know. I think a lot of people feel when they're in situations that are not whatever normal is, whatever that is even mean that they're just they're in isolation, and they're there's nobody that cares and that they don't matter. And I think my biggest thing in my coaching and in my podcast. Have to just say, You know what, we're here, and we really want to understand, if we don't understand, explain it to us. So we do, and that you're not alone in this, and we we're here to help, you know, to collaborate and to help each other.   Michael Hingson ** 55:11 Yeah, well, tell us a little bit more about the whole coaching program, what's what's happening now, what your goals are for that, and and how you're finding people and so on,   Susan Janzen ** 55:22 right? So the coaching my specific areas are confidence and resilience is my is my title, like confidence and resilience coach and I, and I'm going based on my past and the resilience that I've overcome so many different things. So I've got kind of a long list of things every time. So you talk to say, yeah, no, I that's happened to me, but, and just to, just to encourage people to come into either one on one coaching, or I'm going to have group coaching. And on my website, I also want to have drivers where we we create more value, so that if they're a member, then they can get more podcasts that are more about the how tos, like exactly, specifically areas that they might be interested in. And I also want to create a group where we can have, like a one day a week, coffee time, coffee chat, so we can get people together who are in the same boat, especially those parents with children with a breath of me, and just a place where they can just, kind of no agenda, just to chat and and I also would love to have, like a retreat by the end of the year. Let's all gather, and let's just have a day, you know, together, where we can enjoy each other's company. So that's kind of what I'd like to build with my, with my, with my coaching packages, and then also one on one, of course, as well. And that's, yeah, I would like to have a community, like, build a community. So   Michael Hingson ** 56:51 do you do any of your coaching virtually, or is it all in person? Well,   Susan Janzen ** 56:55 right now it's virtual, like, the one coaching I've done so far and but I'm open to either, like, I'm happy to meet people I don't have an office. Um, is that interesting? How, if you would have asked me that question before COVID, bc I would have just had an office somewhere, and where now it's, like, virtual just is so convenient. Yeah? Meeting full and just all the driving I've eliminated, it's been amazing. So, yeah, I would be open to eat it. You know,   Susan Janzen ** 57:27 how far away have you had clients from?   Susan Janzen ** 57:31 Basically, the ones I've had are the ones that I've had up till now. Really, interestingly enough, are local. They're more local people so we could have met for coffee. Yeah,   Michael Hingson ** 57:43 and still might, and we still, I'm   Susan Janzen ** 57:47 sure we will. I'm sure we will, because I keep in touch with them, and they're doing great, but interesting, isn't that interesting? It's a really good question, though, because I'm curious to see you know how far you know, the word will get out to come and join me, you know, in the coaching program, yeah, that'd be human.   Michael Hingson ** 58:08 Well, it sounds like a lot of fun. It sounds like fun, yeah, so why do you still continue to sing? Oh, I   Susan Janzen ** 58:15 can't stop I can't shut up. I just think it's like, even it, yeah, it's too hard for me to stop. It's my joy. That's where I find my you know, even as a kid, going through all the tough times I went through, that was my my joy. It was my vice happy place. So I just   Michael Hingson ** 58:32 so do you think that that singing helps others with confidence and resilience?   Susan Janzen ** 58:36 I um, I think, I think the the techniques that are used in singing, a lot of them are used in podcasting or speaking. A lot of them, we are speakers, for instance. And then they have, they worry about confidence on camera specifically, and when that where light comes on, or when the light comes on, and they just don't know how they're looking or how people are seeing them, those kind of areas, those are the things that I kind of tackle when I talk, talk to them and just explain it as a like, I sang the national anthem for a Stanley Cup playoff game. That's scary, like, that's that's really scary. So I mean, I know I've been there, and I know what that feels like, and I know how your body feels, and I know the importance of breathing, and I think one of the biggest things is just getting people to, just to take deep breaths. You know, when   Michael Hingson ** 59:28 you're when you relax and you lean into it, which I'm sure you do because you're used to it. That gives you a confidence that you can then project onto other people 100% Yeah, exactly. You talked about the red light on the camera coming on. It reminds me of one of my favorite stories. Yeah, right after September 11, I was interviewed on Larry King Live on scene. Oh, wow, wow. We actually had five different interviews, and when the second one occurred, mm. Uh, the the the producer, the director, came into the studio where I was and Larry was still out in California, and I was doing it from CNN in New York. And you know, when they, when they do their shows, everything is like, from sort of the chest up. It's mainly dealing with your face and so on. So for Roselle, excuse me, for Roselle to be able to be my guide dog, to be part of the show, they build a platform that we put her up on. Now she was just laying there. And the director came in and he said, you know, your dog isn't really doing anything. Is there anything we can do to make her more animated? And I said, are the Clea lights on? Because I couldn't really tell and he said, No. I said, then don't worry about it. When those lights come on, she will be a totally different dog, because she figured out cameras. She loved to go in front of the camera. The klieg lights came on, she lifts up her head, she's yawning, she's blinking, she's wagging her tail. It was perfect. Yeah, it's one of my favorite stories. But that is so great. I guess it's also the time to tell you that the name of my third guide dog was, here it comes, Klondike. Oh, really, my third guide dog, anything was a golden retriever. His name was Klondike.   Susan Janzen ** 1:01:18 Oh, that's and I know I'm public dates, and then you got two of us here. This is great. Yeah, that is so cool. Well,   Michael Hingson ** 1:01:26 if people want to reach out and get get in contact with you, they want to learn about your coaching programs and so on. How do they do that?   Susan Janzen ** 1:01:35 So I think the best way is, my website is this, www, dot Sue. Janssen, I'm just going by my short Susan. So S, U, E, J, a, n, z, e n, dot, C, A diamet, and that'll kind of give you everything there. There'll be a little video of my granddaughter on there. There'll be ways to get in touch with me and to book a call. So that would be great. And then we'll chat about it,   Michael Hingson ** 1:01:59 and we have an image of your book cover in in the show notes and so on. And so I hope people will pick that up. Um, I always ask this, although a lot of times it doesn't happen. But does it happen to also be availabl

As we seek God and stay in His presence, we can trust in His promises of love, knowing that He is faithful and true.

In this episode of The Begin Again Podcast, host Gary Menkes sits down with Chris Janssen, a mindset coach, author, and speaker, to discuss her powerful journey through addiction and recovery. Chris opens up about her struggles with alcohol, the internal battles of guilt and self-sabotage, and the profound impact of surrendering control to something greater than herself. After spending years trapped in a cycle of addiction, she finally found clarity, healing, and a renewed sense of purpose through the recovery community.Chris shares how embracing grace, resilience, and personal growth became the foundation of her transformation. She delves into the challenges of self-worth, the power of self-talk, and the importance of choosing words that foster healing and positivity. Now, as a life coach trained under Tony Robbins, Chris uses her experience to help others overcome limiting beliefs and create meaningful change in their lives.Whether you're on your own recovery journey or seeking inspiration for personal growth, this episode offers valuable insights into overcoming addiction, finding strength in vulnerability, and taking the steps necessary to begin again.

Join the conversation in our community at https://butjesusdrankwine.com/community.  Today, we sit down with Chris Janssen, MA, BCC, a board-certified results coach, author, and expert in performance and mindset. Chris shares her deeply personal journey with alcohol, from growing up in a non-drinking household to battling a secretive drinking habit in adulthood. She first got sober in 2007 but went back to alcohol during the pandemic, an experience that brought her to a deeper understanding of grace, community, and personal transformation. Chris discusses the themes of her book, Grace Yourself: How to Show Up for the Sober Life You Want, highlighting the role of self-compassion in recovery, how to navigate perfectionism, and why so many high achievers struggle with alcohol. She also offers practical tools for handling cravings, shifting toxic narratives, and finding a supportive community. Whether you're on your own sobriety journey or supporting a loved one, this episode offers encouragement and actionable steps for embracing a life of freedom and grace. What You'll Learn in This Episode: The importance of grace and self-compassion in the freedom from alcohol journey How to break free from perfectionism and self-sabotage Why high achievers are often drawn to alcohol and unhealthy coping mechanisms Practical tools for handling cravings and shifting negative narratives Connect with Chris: Website: www.chrisjanssencoaching.com Book: Grace Yourself: How to Show Up for the Sober Life You Want Order Christy's book now available! Love Life Sober, A 40 Day Alcohol Fast To Rediscover Your Joy, Improve Your Health and Renew Your Mind  https://a.co/d/fTvdTw6 Learn More about Coaching with Christy https://www.lovelifesober.co.uk/   Learn More about Coaching with Meade https://meadehollandshirley.com/   Connect with us on Instagram! @imnotsoberimfree @lovelifesoberwithchristy @butjesusdrankwine   You can find this episode on YouTube HERE.   The creators, hosts, and producers of the But Jesus Drank Wine podcast are not healthcare practitioners and therefore do not give medical, psychological or professional advice nor do they intend for the podcast, any communication on behalf of BJDW or otherwise to be a substitute for such. Additionally, the views and opinions expressed in any mention of and/or linked resources are those of the authors/owners of those resources and do not necessarily reflect the views or opinions of the But Jesus Drank Wine podcast team or guests of the show.  

God is not honored when our fasting is not connected with a sincere heart of obedience.

Missin Curfew Episode 377 Cam Janssen joins the show to talk some Blues and fighting in the NHL Could the Rangers go on a run if they make it to the playoffs?  Dallas is somehow a sleeper despite fighting for the one seed Cam Fowler might be the best trade of the season After April Fool's the Fellas share some prank stories from when they played SAUCE HOCKEY MERCH | https://saucehockey.com/collections/missin-curfew YOUTUBE | www.youtube.com/@MissinCurfew SPOTIFY | https://open.spotify.com/show/4uNgHhgCtt97nMbbHm2Ken APPLE | https://podcasts.apple.com/us/podcast/missin-curfew INSTAGRAM | www.instagram.com/missincurfew TWITTER | www.twitter.com/MissinCurfew TIKTOK | www.tiktok.com/@missincurfewpod Learn more about your ad choices. Visit podcastchoices.com/adchoices

Brian Janssen, Chief Information Officer for Medicare at WPS Health Insurance, discusses the responsible use of AI in healthcare to improve patient outcomes and reduce costs. He highlights the opportunity to enhance healthcare literacy in response to events from 2024 and shares valuable advice for emerging healthcare leaders.

Chris, a seasoned life coach with a master's in counseling psychology, shares her profound journey from addiction to freedom, offering a fresh perspective on perfectionistic tendencies and self-sabotage. Chris candidly reflects on her experiences with alcohol addiction, the misconceptions around sobriety, and the societal pressures that often accompany the decision to live alcohol-free.  Her book, "Grace Yourself," offers a beacon of hope for those navigating their own battles.Get the book:  Grace Yourself: How to Show Up for the Sober Life You Want by Chris Janssen: https://amzn.to/4gJuvVq https://www.chrisjanssencoaching.com/Revitalize your faith and fitness with a morning routine that does not sacrifice your sleep and does start each day with God's Word and a workout. Join the community today at www.earlymorninghabit.com ☀️ Grab my FREE TRAINING on 3 Powerful Secrets to Rise Renewed Every Morning.☀️ Join the Early Morning Habit course and community today.➡️ Find Our Favorite Resources at the Early Morning Habit Amazon Shop =============================SUBSCRIBE & FOLLOW ============================= ➡️ YouTube➡️ InstagramWe value your feedback! Please share your thoughts on this show here. This episode is NOT sponsored. Some product links are affiliate links; we will receive a small commission if you buy something.

Here's the human struggle—we have ALL attached ourselves to something holding us back. Check out this transformative conversation with results, performance, and mindset coach Chris Janssen. She discusses what keeps you from closing the gap between where you are and where you want to be.   Chris has helped has a passion for coaching people to get where they want to go in life. She's also getting honest about the struggle that was holding her back!   She's the real deal, and her journey of recovery from alcohol addiction and her empowering coaching skills will inspire you, so get ready to get coached!   If you're ready to show up to your life sober and free, no matter your struggle, don't skip this episode!  Today, you'll hear: What addiction is and how to know when you stop Why identity is key to recovery The three steps that we all need to be doing A powerful question you need to be asking yourself Connect with Chris here: Website / Instagram Quoteworthy: "People need to get honest about the cost of the thing they want to move away from and weigh it against the cost of not giving it up." This is our LAST ALL-VIRTUAL training! If you're ready to break out of body shame, join Revelation Wellness in our next platoon of Revelation Wellness Instructor Training or LiveWell Health Coach Training brigade. Download a packet to explore our Revelation Wellness training programs. You can also learn more about our RW+ Membership and Food and Body Addiction Group here [link].  Get connected: revelationwellness.org | Instagram | YouTube Please consider following this show (and sharing it with a friend), leaving a review, and telling us what you think with a voice message! If you leave us a voice message, be sure to include the episode number. Follow | Leave a Review | Send a Voice Message *By leaving a SpeakPipe voice message, you agree that Revelation Wellness may use your voice message for podcast, promotional, and website content.